Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-016-4
CAS number: 13586-84-0
Acute oral toxicity:LD50(female rats)>2000mg/kg bwAcute toxicity, dermal:Conduct of an acute dermal toxicity study is unjustified since dermal uptake is considered negligible (cf. Annex VIII section 8.5 Column 2 of regulation (EC) 1907/2006).Acute toxicity, inhalation:Testing is technically not feasible.
reference Finlay (2007) and Schmidt et al. (1975) are considered as the
key studies for acute oral toxicity and will be used for classification.
According to Finlay (2007) female CD(SD) rats were dosed at 175, 550 and
2000 mg/kg orally via gavage. During the conduct of the study no
mortalities occurred at the highest dose group
rat >2000 mg/kg bw
to Schmidt et al. (1975) female rats received a total dose of 150 mg
cobalt stearate/ml. The LD50 for female rats was calculated to be 2390
mg/kg bw with a 95% confidence interval of 2130 to 2670.
classification criteria according to regulation (EC) 1272/2008 as
acutely toxic are not met since the ATE is above 2000 mg/kg body-weight,
hence no classification required.
target organ toxicant (STOT) – single exposure: oral
classification criteria acc. to regulation (EC) 1272/2008 as specific
target organ toxicant (STOT) – single exposure, oral are not met since
no reversible or irreversible adverse health effects were observed
immediately or delayed after exposure and no effects were
observed at the guidance value, oral for a Category 1 classification of
300 mg/kg bw and at the guidance value, oral for a Category 2
classification of 2000 mg/kg bw. No classification required.
an acute dermal toxicity study is unjustified since dermal uptake is
target organ toxicant (STOT) – single exposure: dermal
inhalation toxicity and Specific
target organ toxicant (STOT) – single exposure: inhalation
to section 2, annex XI of regulation (EC) 1907/2006, the conduct of an
acute toxicity study via inhalation for cobalt stearate is omitted. The
substance is placed on the market and used as solid lumps with a
particle size of >> 1 mm.
In order to assess the tendency of cobalt
stearate lumps to generate fine particles via abrasion, a friability
test was conducted (see Physical chemical properties/particle size
distribution section for further details.The
total amount of abraded material was 1.5% of the starting material. The
total dustiness (airborne fraction) of the abraded fraction was 0.237%
based on the total amount of starting material, with a mass median
aerodynamic diameter of airborne fraction of MMAD=28.63 µm, GSD=4.72.
The fractional deposition in human respiratory tract (MPPD model, based
on calculated MMAD) is: Head (ET): 45.1 %, Tracheobronchial (TB): 0.1 %,
Pulmonary (PU): 0.1 %.
on the above information it is concluded that cobalt stearate is not
likely to generate elevated amounts of abraded particles under
conditions of severe shear stress, hence is not capable creating an
inhalable atmosphere, thus testing is technically not feasible.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again